Advertisement
U.S. markets close in 1 minute
  • S&P 500

    5,256.63
    +8.14 (+0.16%)
     
  • Dow 30

    39,820.43
    +60.35 (+0.15%)
     
  • Nasdaq

    16,384.46
    -15.06 (-0.09%)
     
  • Russell 2000

    2,121.45
    +7.11 (+0.34%)
     
  • Crude Oil

    82.99
    +1.64 (+2.02%)
     
  • Gold

    2,241.10
    +28.40 (+1.28%)
     
  • Silver

    24.98
    +0.23 (+0.92%)
     
  • EUR/USD

    1.0791
    -0.0039 (-0.36%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2622
    -0.0016 (-0.13%)
     
  • USD/JPY

    151.3860
    +0.1400 (+0.09%)
     
  • Bitcoin USD

    70,868.81
    +2,145.96 (+3.12%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

ABMD, IFF & GVA - Class Action Update - Bronstein, Gewirtz & Grossman, LLC

NEW YORK, NY / ACCESSWIRE / October 4, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Abiomed, Inc. (ABMD)
Class Period: January 31, 2019 - July 31, 2019
Deadline: October 7, 2019
For more info:www.bgandg.com/abmd

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:(1) ABIOMED's revenue growth was in decline; (2) the Company did not have a sufficient plan in place to stem its declining revenue growth; (3) the Company was unlikely to restore its revenue growth over the next several fiscal quarters; (4) consequently, ABIOMED was reasonably likely to revise its full-year 2020 guidance in a way that would fall short of the Company's prior projections and market expectations; and (5) as a result, the Company's public statements were materially false and misleading at all relevant times.

International Flavors & Fragrances Inc. (IFF)
Class Period:
May 7, 2018 - August 5, 2019
Deadline: October 11, 2019
For more info:www.bgandg.com/iff

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:(1) that Frutarom had bribed customers in Russia and Ukraine; (2) that senior management at Frutarom were aware of such improper payments; (3) that, as a result, Frutarom's financial results were materially overstated; (4) that, as a result of the improper payments, the Company was reasonably likely to face regulatory scrutiny; (5) that the Company had not completed adequate due diligence before acquiring Frutarom; (6) that, as a result of the foregoing, the Company was unlikely to achieve purported synergies from the acquisition; and (7) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Granite Construction Incorporated (GVA)
Class Period:
October 26, 2018 - August 1, 2019
Deadline: October 15, 2019
For more info:www.bgandg.com/gva

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company had assumed certain risks in connection with its heavy civil joint venture projects bid between 2012 and 2014; (2) there was an "untenable" imbalance of risk sharing between the Company and the joint venture project owners; (3) the Company was reasonably likely to incur additional project costs for its joint venture projects; (4) the Company was reasonably likely to incur additional costs in connection with certain project disputes; and (5) as a result, Granite Construction's public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 |info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC



View source version on accesswire.com:
https://www.accesswire.com/560588/ABMD-IFF-GVA--Class-Action-Update--Bronstein-Gewirtz-Grossman-LLC

Advertisement